Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schuler

Showing results (251-260 of 300) with videos related to

Pageof 30
Sort By:
Breast Cancer Research and Treatment|October 15, 2013
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsAnja Welt, Mitra Tewes, Bahriye Aktas, et al.
Oncology Research and Treatment|January 31, 2023
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy ProtocolsJulius Roehrle, Stefan Kasper, Jürgen-Walter Treckmann, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2026
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphomaElena Garralda, Patrick Schöffski, Arjun Oberoi, et al.
The New England Journal of Medicine|March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
Translational Lung Cancer Research|July 17, 2025
The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitisAndreas Herz, Maja Guberina, Christoph Pöttgen, et al.
Journal of Cancer Research and Clinical Oncology|December 22, 2015
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patientsJens Köhler, Martin Schuler, Thomas Christoph Gauler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)|November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summaryGrace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
The New England Journal of Medicine|August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsDavid M Hyman, Igor Puzanov, Vivek Subbiah, et al.
The New England Journal of Medicine|June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
Pageof 30

Showing results (251-260 of 300) with videos related to

Sort By:
Pageof 30
Breast Cancer Research and Treatment|October 15, 2013
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsAnja Welt, Mitra Tewes, Bahriye Aktas, et al.
Oncology Research and Treatment|January 31, 2023
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy ProtocolsJulius Roehrle, Stefan Kasper, Jürgen-Walter Treckmann, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2026
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphomaElena Garralda, Patrick Schöffski, Arjun Oberoi, et al.
The New England Journal of Medicine|March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
Translational Lung Cancer Research|July 17, 2025
The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitisAndreas Herz, Maja Guberina, Christoph Pöttgen, et al.
Journal of Cancer Research and Clinical Oncology|December 22, 2015
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patientsJens Köhler, Martin Schuler, Thomas Christoph Gauler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)|November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summaryGrace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
The New England Journal of Medicine|August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsDavid M Hyman, Igor Puzanov, Vivek Subbiah, et al.
The New England Journal of Medicine|June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
Pageof 30